{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T19:10:54Z","timestamp":1774120254811,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,12,13]],"date-time":"2012-12-13T00:00:00Z","timestamp":1355356800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1007\/s10096-012-1788-2","type":"journal-article","created":{"date-parts":[[2012,12,12]],"date-time":"2012-12-12T14:08:43Z","timestamp":1355321323000},"page":"647-655","source":"Crossref","is-referenced-by-count":6,"title":["Cost-effectiveness of rifampin for 4\u00a0months and isoniazid for 9\u00a0months in the treatment of tuberculosis infection"],"prefix":"10.1007","volume":"32","author":[{"given":"J. M.","family":"Pina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Clotet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. R.","family":"Sala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Salleras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,12,13]]},"reference":[{"key":"1788_CR1","unstructured":"World Health Organization (WHO) (2011) Global tuberculosis control. WHO report, pp 1\u201328"},{"key":"1788_CR2","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1098\/rsif.2007.1138","volume":"5","author":"C Dye","year":"2008","unstructured":"Dye C, Williams BG (2008) Eliminating human tuberculosis in the twenty-first century. J R Soc Interface 5:653\u2013662","journal-title":"J R Soc Interface"},{"key":"1788_CR3","unstructured":"Rieder HL (2002) Interventions for tuberculosis control and elimination. International Union Against Tuberculosis and Lung Disease, Paris, pp 15\u201395, 127\u2013147"},{"key":"1788_CR4","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1164\/rccm.200901-0153OC","volume":"179","author":"DP Holland","year":"2009","unstructured":"Holland DP, Sanders GD, Hamilton CD, Stout JE (2009) Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. Am J Respir Crit Care Med 179:1055\u20131060","journal-title":"Am J Respir Crit Care Med"},{"key":"1788_CR5","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.5588\/ijtld.10.0575","volume":"15","author":"K Esfahani","year":"2011","unstructured":"Esfahani K, Aspler A, Menzies D, Schwartzman K (2011) Potential cost-effectiveness of rifampin vs. isoniazid for latent tuberculosis: implications for future clinical trials. Int J Tuberc Lung Dis 15:1340\u20131346","journal-title":"Int J Tuberc Lung Dis"},{"issue":"RR-15","key":"1788_CR6","first-page":"1","volume":"54","author":"National Tuberculosis Controllers Association","year":"2005","unstructured":"National Tuberculosis Controllers Association; Centers for Disease Control and Prevention (CDC) (2005) Guidelines for the investigation of contacts of persons with infectious tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep 54(RR-15):1\u201347","journal-title":"MMWR Recomm Rep"},{"issue":"RR-6","key":"1788_CR7","first-page":"1","volume":"49","author":"ATS\/CDC Statement Committee on Latent Tuberculosis Infection","year":"2000","unstructured":"ATS\/CDC Statement Committee on Latent Tuberculosis Infection (2000) Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep 49(RR-6):1\u201351","journal-title":"MMWR Recomm Rep"},{"key":"1788_CR8","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","volume":"174","author":"JJ Saukkonen","year":"2006","unstructured":"Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB, Bernardo J, Venkataramanan R, Sterling TR; ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee (2006) An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 174:935\u2013952","journal-title":"Am J Respir Crit Care Med"},{"key":"1788_CR9","first-page":"19","volume-title":"Cost-effectiveness analysis in health: a practical approach","author":"P Muennig","year":"2008","unstructured":"Muennig P (2008) Cost-effectiveness analysis in health: a practical approach, 2nd edn. Jossey-Bass, San Francisco, pp 19\u201335","edition":"2"},{"key":"1788_CR10","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1111\/j.1469-0691.2010.03331.x","volume":"16","author":"MD Zilberberg","year":"2010","unstructured":"Zilberberg MD, Shorr AF (2010) Understanding cost-effectiveness. Clin Microbiol Infect 16:1707\u20131712","journal-title":"Clin Microbiol Infect"},{"key":"1788_CR11","unstructured":"Agencia Espa\u00f1ola de Medicamentos (2006) Informaci\u00f3n de medicamentos autorizados en Espa\u00f1a. Ministerio de Sanidad y Consumo. In: Guia de prescrici\u00f3n terap\u00e9utica (GPT): Pharma, Barcelona: 309"},{"key":"1788_CR12","unstructured":"Institut Catal\u00e0 de la Salut (2008) Resoluci\u00f3 slt\/434\/2008, de 12 de Febrer: Revisi\u00f3 de preus p\u00fablics corresponents als serveis sanitaris que presta l\u2019Institut Catal\u00e0 de la Salut. Diari Oficial de la Generalitat de Catalunya N\u00fam 5076\u201322. February 2008"},{"key":"1788_CR13","unstructured":"Nomenclator del Colegio Oficial de M\u00e9dicos de Barcelona (2009) Available online at: http:\/\/www.comb.cat\/nomenclator . Accessed 7 Feb 2011"},{"issue":"RR-11","key":"1788_CR14","first-page":"1","volume":"52","author":"American Thoracic Society","year":"2003","unstructured":"American Thoracic Society; CDC; Infectious Diseases Society of America (2003) Treatment of tuberculosis. MMWR Recomm Rep 52(RR-11):1\u201377","journal-title":"MMWR Recomm Rep"},{"key":"1788_CR15","unstructured":"Agencia de Calidad del Servicio Nacional de Salud, Instituto de Informaci\u00f3n Sanitaria (2009) Norma estatal de los AP GRD v23. Ministerio de Sanidad, Pol\u00edtica Social e Igualdad: Spain. Available online at: http:\/\/www.mspsi.es\/estadEstudios\/estadisticas\/cmbd.htm . Accessed 11 Feb 2011"},{"key":"1788_CR16","first-page":"555","volume":"60","author":"International Union Against Tuberculosis Committee on Prophylaxis","year":"1982","unstructured":"International Union Against Tuberculosis Committee on Prophylaxis (1982) Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 60:555\u2013564","journal-title":"Bull World Health Organ"},{"key":"1788_CR17","unstructured":"World Health Organization (WHO) (2008) Anti-tuberculosis drug resistance in the world. Report no. 4, pp 35\u201353"},{"key":"1788_CR18","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1017\/S0950268897007917","volume":"119","author":"E Vynnycky","year":"1997","unstructured":"Vynnycky E, Fine PE (1997) The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. Epidemiol Infect 119:183\u2013201","journal-title":"Epidemiol Infect"},{"key":"1788_CR19","first-page":"1112","volume":"14","author":"O Mor\u00e1n-Mendoza","year":"2010","unstructured":"Mor\u00e1n-Mendoza O, Marion SA, Elwood K, Patrick D, FitzGerald JM (2010) Risk factors for developing tuberculosis: a 12-year follow-up of contacts of tuberculosis cases. Int J Tuberc Lung Dis 14:1112\u20131119","journal-title":"Int J Tuberc Lung Dis"},{"key":"1788_CR20","first-page":"3","volume-title":"Tuberculosis and nontuberculous mycobacterial infections","author":"AK Dutt","year":"1999","unstructured":"Dutt AK, Stead WW (1999) Epidemiology and host factors. In: Schlossberg D (ed) Tuberculosis and nontuberculous mycobacterial infections. W. B. Saunders, Philadelphia, pp 3\u201316"},{"key":"1788_CR21","first-page":"793","volume-title":"Reichman and Hershfield\u2019s tuberculosis: a comprehensive, international approach","author":"EA Nardel","year":"2006","unstructured":"Nardel EA, Fennelly KP (2006) Tuberculosis transmission and infection control in congregate settings. In: Raviglione MC (ed) Reichman and Hershfield\u2019s tuberculosis: a comprehensive, international approach. Informa Healthcare, London, pp 793\u2013821"},{"key":"1788_CR22","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1164\/rccm.200405-584PP","volume":"170","author":"LB Reichman","year":"2004","unstructured":"Reichman LB, Lardizabal A, Hayden CH (2004) Considering the role of four months of rifampin in the treatment of latent tuberculosis infection. Am J Respir Crit Care Med 170:832\u2013835","journal-title":"Am J Respir Crit Care Med"},{"key":"1788_CR23","first-page":"115","volume-title":"Evidence-based medicine","author":"SE Straus","year":"2006","unstructured":"Straus SE, Glasziou P, Richardson WS, Haynes RB (2006) Evidence-based medicine. Elsevier, Madrid, pp 115\u2013177, 263\u2013277"},{"key":"1788_CR24","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1157\/13116320","volume":"130","author":"JM Pina-Guti\u00e9rrez","year":"2008","unstructured":"Pina-Guti\u00e9rrez JM, Ferrer-Traid A, Arias C, Sala-Farr\u00e9 MR, L\u00f3pez-Sanmart\u00edn JL (2008) Adherence and effectiveness of the treatment of latent tuberculosis infection with isoniazid for 9\u00a0months in a cohort of 755 patients. Med Clin (Barc) 130:165\u2013171","journal-title":"Med Clin (Barc)"},{"key":"1788_CR25","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1157\/13089668","volume":"24","author":"C Bran","year":"2006","unstructured":"Bran C, G\u00f3mez i Prat J, Cayl\u00e1 JA, Garc\u00eda de Olalla P (2006) Factors associated with latent tuberculous infection in immigrants less than 35\u00a0years old. Enferm Infecc Microbiol Clin 24:322\u2013325","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"1788_CR26","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1164\/rccm.200404-478OC","volume":"170","author":"D Menzies","year":"2004","unstructured":"Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K (2004) Treatment completion and costs of a randomized trial of rifampin for 4\u00a0months versus isoniazid for 9\u00a0months. Am J Respir Crit Care Med 170:445\u2013449","journal-title":"Am J Respir Crit Care Med"},{"key":"1788_CR27","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1001\/archinte.166.17.1863","volume":"166","author":"KR Page","year":"2006","unstructured":"Page KR, Sifakis F, Montes de Oca R, Cronin WA, Doherty MC, Federline L et al (2006) Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med 166:1863\u20131870","journal-title":"Arch Intern Med"},{"key":"1788_CR28","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1378\/chest.130.6.1712","volume":"130","author":"A Lardizabal","year":"2006","unstructured":"Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman LB (2006) Enhancement of treatment completion for latent tuberculosis infection with 4\u00a0months of rifampin. Chest 130:1712\u20131717","journal-title":"Chest"},{"key":"1788_CR29","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/0003-4819-149-10-200811180-00003","volume":"149","author":"D Menzies","year":"2008","unstructured":"Menzies D, Long R, Trajman A, Dion MJ, Yang J, Al Jahdali H et al (2008) Adverse events with 4\u00a0months of rifampin therapy or 9\u00a0months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med 149:689\u2013697","journal-title":"Ann Intern Med"},{"key":"1788_CR30","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1086\/647944","volume":"49","author":"PD Ziakas","year":"2009","unstructured":"Ziakas PD, Mylonakis E (2009) 4\u00a0months of rifampin compared with 9\u00a0months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Clin Infect Dis 49:1883\u20131889","journal-title":"Clin Infect Dis"},{"key":"1788_CR31","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1164\/ajrccm\/145.1.36","volume":"145","author":"Hong Kong Chest Service\/Tuberculosis Research Centre","year":"1992","unstructured":"Hong Kong Chest Service\/Tuberculosis Research Centre; Madras\/British Medical Research Council (1992) A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 145:36\u201341","journal-title":"Am Rev Respir Dis"},{"key":"1788_CR32","first-page":"91","volume-title":"M\u00e9todos de investigaci\u00f3n aplicados a la atenci\u00f3n primaria de salud","author":"JM Argim\u00f3n","year":"1995","unstructured":"Argim\u00f3n JM, Jim\u00e9nez J (1995) M\u00e9todos de investigaci\u00f3n aplicados a la atenci\u00f3n primaria de salud. Mosby\/Doyma Libros, Barcelona, pp 91\u2013100"},{"key":"1788_CR33","first-page":"847","volume":"3","author":"GW Comstock","year":"1999","unstructured":"Comstock GW (1999) How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 3:847\u2013850","journal-title":"Int J Tuberc Lung Dis"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-012-1788-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-012-1788-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-012-1788-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T09:35:04Z","timestamp":1559122504000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-012-1788-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,13]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["1788"],"URL":"https:\/\/doi.org\/10.1007\/s10096-012-1788-2","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,13]]}}}